Evidence map›Paper›PMID 38480795›Full record

ArticleEuropean journal of human genetics : EJHG2024

Systematic reanalysis of genomic data by diagnostic laboratories: a scoping review of ethical, economic, legal and (psycho)social implications.

Marije A van der Geest, Els L M Maeckelberghe, Marielle E van Gijn, Anneke M Lucassen, Morris A Swertz, Irene M van Langen, Mirjam Plantinga

Abstract readScoping Review
In one paragraph

Article in European journal of human genetics : EJHG, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Novel insights into cancer predisposition genes.European journal of human genetics : EJHG · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marije A van der GeestDepartment of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. m.a.van.der.geest@umcg.nl.ORCID 0000-0002-1919-6547
Els L M MaeckelbergheInstitute for Medical Education, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0002-3983-6089
Marielle E van GijnDepartment of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0002-1073-0539
Anneke M LucassenFaculty of Medicine, Clinical Ethics and Law, University of Southampton, Southampton, UK.ORCID 0000-0003-3324-4338
Morris A SwertzDepartment of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0002-0979-3401
Irene M van LangenDepartment of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0002-0960-7154
Mirjam PlantingaDepartment of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the introduction of Next Generation Sequencing (NGS) techniques increasing numbers of disease-associated variants are being identified. This ongoing progress might lead to diagnoses in formerly undiagnosed patients and novel insights in already solved cases. Therefore, many studies suggest introducing systematic reanalysis of NGS data in routine diagnostics. Introduction will, however, also have ethical, economic, legal and (psycho)social (ELSI) implications that Genetic Health Professionals (GHPs) from laboratories should consider before possible implementation of systematic reanalysis. To get a first impression we performed a scoping literature review. Our findings show that for the vast majority of included articles ELSI aspects were not mentioned as such. However, often these issues were raised implicitly. In total, we identified nine ELSI aspects, such as (perceived) professional responsibilities, implications for consent and cost-effectiveness. The identified ELSI aspects brought forward necessary trade-offs for GHPs to consciously take into account when considering responsible implementation of systematic reanalysis of NGS data in routine diagnostics, balancing the various strains on their laboratories and personnel while creating optimal results for new and former patients. Some important aspects are not well explored yet. For example, our study shows GHPs see the values of systematic reanalysis but also experience barriers, often mentioned as being practical or financial only, but in fact also being ethical or psychosocial. Engagement of these GHPs in further research on ELSI aspects is important for sustainable implementation.

Indexed as

Genetic TestingGenomicsHigh-Throughput Nucleotide SequencingHumansLaboratories, Clinical

Identifiers

PMID38480795
PMCPMC11061183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.